Ladarixin

• CAT Number: I007608
• CAS Number: 849776-05-2
• Molecular Formula: C11H12F3NO6S2
• Molecular Weight: 375.34
• Purity: ≥95%
• Synonyms: [4-[(2R)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] trifluoromethanesulfonate
• InChI: InChI=1S/C11H12F3NO6S2/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14/h3-7H,1-2H3,(H,15,16)/t7-/m1/s1
• InChIKey: DDLPYOCJHQSVSZ-SSDOTTSWSA-N
• SMILES: C[C@H](C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C

Ladarixin（Cat No.:I007608）is an experimental small-molecule inhibitor targeting the interleukin-8 (IL-8) receptors CXCR1 and CXCR2. By blocking these chemokine receptors, Ladarixin interferes with neutrophil recruitment and activation, thereby reducing inflammation and tissue damage. It has shown therapeutic potential in conditions such as type 1 diabetes, inflammatory skin diseases, and certain cancers where IL-8-mediated immune responses are pathogenic. Ladarixin is especially valuable in studies investigating innate immune modulation, autoimmune disease mechanisms, and tumor microenvironment dynamics. It is intended strictly for use in preclinical research and not for human or veterinary applications.